CSL Salute del bilancio

Salute finanziaria criteri di controllo 4/6

CSL ha un patrimonio netto totale di $20.5B e un debito totale di $10.4B, che porta il suo rapporto debito/patrimonio netto a 50.4%. Le sue attività totali e le sue passività totali sono rispettivamente $38.4B e $17.9B. L'EBIT di CSL è $4.1B rendendo il suo rapporto di copertura degli interessi 9.5. Ha liquidità e investimenti a breve termine pari a $1.5B.

Informazioni chiave

50.4%

Rapporto debito/patrimonio netto

US$10.37b

Debito

Indice di copertura degli interessi	9.5x
Contanti	US$1.52b
Patrimonio netto	US$20.55b
Totale passività	US$17.90b
Totale attività	US$38.45b

Aggiornamenti recenti sulla salute finanziaria

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

Recent updates

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 43% Above Its Share Price

Jan 10

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

Nov 01

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Sep 03

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 16

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Aug 07

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

May 22

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $11.3B ) di CSL superano le sue passività a breve termine ( $6.1B ).

Passività a lungo termine: Le attività a breve termine di CSL ( $11.3B ) non coprono le sue passività a lungo termine ( $11.8B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 43% ) di CSL è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di CSL si è ridotto da 75.4% a 50.4% negli ultimi 5 anni.

Copertura del debito: Il debito di CSL è ben coperto dal flusso di cassa operativo ( 28.5% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di CSL sono ben coperti dall'EBIT ( 9.5 x copertura).

Bilancio

Scoprire le aziende sane

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/05/02 19:27
Prezzo dell'azione a fine giornata	2025/05/02 00:00
Guadagni	2024/12/31
Guadagni annuali	2024/06/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

CSL Limited è coperta da 29 analisti. 17 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Saul Hadassin	Barrenjoey Markets Pty Limited
Thomas Wakim	Bell Potter
Lyanne Harrison	BofA Global Research

CSL Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Recent updates

Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog

CSL is undervalued in High Tax Scenario

Upcoming dividend of US$1.30 per share

Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position

CSL and Arcturus Therapeutics Announces Marketing Authorization Grant by European Commission Marketing Authorization for Kostaive (Arct-154), A Self-Amplifying Mrna Covid-19 Vaccine

European Commission Approves CSL's ANDEMBRY®? (Garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)

First half dividend of US$1.30 announced

First half 2025 earnings: EPS and revenues miss analyst expectations

Joy Linton Resumes the Role of Chief Financial Officer of CSL Limited

CSL Behring's Gene Therapy HEMGENIX®? (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Should You Be Adding CSL (ASX:CSL) To Your Watchlist Today?

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 43% Above Its Share Price

CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Upcoming dividend of US$1.45 per share

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Final dividend of US$1.45 announced

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

Upcoming dividend of US$1.07 per share at 1.1% yield

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Independent Non Executive Director recently bought AU$74k worth of stock

Consensus forecasts updated

Now 20% undervalued

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Now 20% undervalued

MD, CEO & Executive Director exercised options and sold AU$4.7m worth of stock

Non-Independent Non-Executive Director recently sold AU$6.4m worth of stock

Upcoming dividend of US$1.18 per share

Non-Independent Non-Executive Director exercised options to buy AU$11m worth of stock.

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Analisi della posizione finanziaria